Dr Noble’s Takeaway
- GSM is one condition with many faces. Vaginal dryness, painful sex, urinary urgency and recurrent urinary tract infections are usually driven by the same thing.
- Hot flashes tend to pass. GSM does not. Left alone, it generally gets worse rather than better.
- It is the most common consequence of menopause that almost nobody is treated for. Fewer than one in ten women with a GSM diagnosis fills a prescription for vaginal estrogen.
- The FDA removed the boxed warning from vaginal estrogen in November 2025. The label that frightened a generation of women and their doctors is gone.

Most women who have GSM have never heard the term. Many have heard a different one from every clinician they have seen: atrophy, dryness, recurrent cystitis, an overactive bladder, a sensitive bladder.
Genitourinary syndrome of menopause is the name for all of it at once. It was agreed in 2014, by The Menopause Society and the International Society for the Study of Women’s Sexual Health, to replace the older term vulvovaginal atrophy. The old name described only part of the picture and, frankly, nobody wanted to say it out loud.
Here is what the new name is trying to capture.
One condition wearing several disguises
GSM covers the genital, sexual and urinary symptoms that follow falling estrogen. In practice that means some combination of the following.
- Vaginal dryness, burning, itching or general soreness
- Pain with sex, often described as tearing, stinging, tightness, ground glass or sandpaper
- Changes in arousal, lubrication or orgasm
- Bleeding or spotting after sex, from tissue that has become fragile
- Urinary urgency and frequency, the feeling of needing to go and needing to go now
- Pain or stinging when passing urine, with no infection present
- Leaking, on coughing, laughing or on the way to the bathroom
- Urinary tract infections that keep returning
- Vaginal Odor, change in odor or change in discharge
- Pelvic pressure
What matters here is the word syndrome. These are not ten plus problems. They are one problem presenting in many different ways, and that is why treating them one at a time so often fails.
It is also worth saying that the symptoms do not all arrive together, and some women get only one. Urinary symptoms alone, with no dryness at all, are a common presentation and one of the most frequently missed.
Why it happens
The vagina, vulva, urethra and bladder base are all responsive to estrogen. They share an embryological origin, and they share receptors. When estrogen falls, they all change.
The tissue becomes thinner and loses elasticity. Blood flow drops, and with it natural lubrication, because vaginal moisture comes largely from fluid passing out of blood vessels in the vaginal wall.
The acidity changes too. Estrogen supports the lactobacilli that keep the vagina acidic, and as estrogen falls those bacteria decline and the pH rises. A more alkaline environment is a more welcoming one for the organisms that cause urinary tract infections. This is the mechanism behind recurrent UTIs after menopause, and it is why antibiotics alone so rarely end the cycle.
None of this is a hygiene problem, and none of it is caused by anything a woman did or did not do.
This is the symptom that does not pass
GSM is progressive and often worsens with time if left untreated..
Common, treatable, and almost never treated
Estimates of how many postmenopausal women have GSM vary enormously, from around 13% to 87%, depending on how a study asks the question. Most research puts it above half, and the symptoms can begin in perimenopause rather than waiting for the final period.
The treatment figures are harder to look at. In a review of more than 1.8 million female Medicare beneficiaries carrying a GSM diagnosis, fewer than one in ten had ever filled a prescription for vaginal estrogen.
That gap has several causes, and only some of them sit with patients. Women do not raise these symptoms because they assume nothing can be done, or because they are embarrassed. Clinicians do not ask. Appointments are short, and this topic rarely makes it onto the list. When nobody asks and nobody volunteers, a very treatable condition goes untreated for years with significant consequences and costs.



The infection cycle deserves its own mention
If you are having urinary tract infections two, three or four times a year after menopause, and each one is being handled with another course of antibiotics, something is being missed.
Recurrent UTI in a postmenopausal woman is a GSM symptom until proven otherwise. Local vaginal estrogen reduces recurrent UTI episodes by roughly half in women with a history of them, and the 2025 guideline on GSM from the American Urological Association, developed with two other societies and endorsed by The Menopause Society, treats this as established.
There is a wider reason to care about this. Repeat antibiotic courses carry their own consequences, for the individual and for antimicrobial resistance generally. Treating the cause rather than each episode is better medicine.
What treatment involves
The 2025 guideline is deliberately not a ladder. There is no requirement to fail one thing before trying another, and the right starting point depends on your symptoms, your history and your preferences.
The options fall into a few groups.
Local vaginal estrogen has the strongest evidence of anything available. It is applied directly to the tissue in a low dose, with minimal absorption into the bloodstream, which makes it quite different from systemic hormone therapy. It addresses the cause rather than the symptom. Estrogens for local therapy can come as creams, tablets, suppositories or rings.
Vaginal prasterone, (DHEA) and ospemifene are alternatives with good evidence, suiting women who prefer a non-estrogen option or who have not done well on vaginal estrogen. Ospemifene is oral and can be associated with an increased risk of clot/stroke/VTE and so I do not consider this first line for the treatment of GSM.
Moisturizers and lubricants genuinely help, and lubricants in particular make an immediate difference to comfort during sex. They do not change the tissue itself, so they work best alongside treatment rather than instead of it.
Pelvic floor physical therapy is worth knowing about, particularly where leaking or pelvic floor tension is part of the picture.
Two practical points. Comfort usually improves within a few weeks, while urinary symptoms and infection prevention take longer, often around three months, so give treatment time before judging it. And because GSM is driven by an ongoing hormonal state, symptoms generally return if treatment stops. This is managed long term, in the way that blood pressure is managed long term.
On energy-based devices, meaning vaginal laser and radiofrequency: the 2025 guideline does not recommend them for GSM, on the basis that the evidence does not support them. I mention it because these are marketed heavily and are expensive.
The warning label is gone
For two decades, vaginal estrogen carried a boxed warning about cardiovascular disease, breast cancer and dementia. That warning was generalized from the Women’s Health Initiative study of systemic hormone therapy and applied to every estrogen product, including local vaginal preparations that barely enter the bloodstream.
It was never supported by the evidence for local treatment, and it did real harm. Women read the leaflet and did not start. Pharmacists flagged it. Clinicians hesitated to prescribe.
On November 10, 2025, the FDA removed it. The Menopause Society supported the decision, as did the professional bodies in urology and urogynecology.
If you were put off vaginal estrogen by that label, or if you were told years ago that it was risky, the advice you were given reflected the labeling of the time rather than the evidence. It is worth revisiting.
What to do with this
If any of the above sounds familiar, the single most useful thing you can do is name it at your next appointment. Say the words: I think I may have genitourinary syndrome of menopause. It changes the conversation, because it asks about a cause instead of listing complaints.
It is reasonable to expect an examination, a discussion of what is driving the symptoms, and a treatment plan with a follow-up to check whether it worked.
One thing that always needs separate attention: any bleeding after twelve period-free months must be evaluated, and should never be assumed to be fragile tissue, even when fragile tissue is the most likely answer.
And if you are not getting anywhere, look for a clinician with specific menopause training. This is one of the conditions where that training makes the most difference, because the treatment is straightforward once somebody recognizes what they are looking at.
Genitourinary syndrome of menopause. It is the agreed term for the genital, sexual and urinary symptoms caused by falling estrogen, introduced in 2014 to replace vulvovaginal atrophy.
Vaginal dryness, burning or itching, pain with sex, bleeding after sex, urinary urgency and frequency, stinging when passing urine, leaking, and recurrent urinary tract infections. Most women have some of these rather than all.
GSM is the broader term. Vulvovaginal atrophy described the vaginal tissue changes only, while GSM includes the urinary symptoms that come from the same cause.
No. Unlike hot flashes, which usually settle over time, GSM is progressive and tends to worsen without treatment, because the underlying low estrogen state persists.
Yes, and this is one of its most common presentations. Falling estrogen raises vaginal pH and reduces protective lactobacilli, which makes infection more likely. There are likely other contributing factors related to the changes in the mucosa, the biome and the urethra. Recurrent UTIs after menopause should prompt an assessment for GSM.
It can contribute to both urgency and leaking, because the urethra and bladder base are estrogen sensitive. Other causes exist as well, which is why an examination matters rather than assuming.
Yes. Symptoms can begin during perimenopause, while periods are still happening. Around 15% of women report these symptoms before menopause itself.
Local vaginal estrogen is applied in a low dose directly to the tissue, with minimal absorption into the bloodstream, and it is not the same as systemic hormone therapy. Because there is limited absorption, no endometrial protection is needed. The FDA removed the boxed warning from these products in November 2025.
Vaginal comfort usually improves within a few weeks. Urinary symptoms and protection against recurrent infection take longer, often around three months of consistent use.
Generally yes. Because GSM is driven by an ongoing hormonal state rather than a one-off event, symptoms tend to return when treatment stops, so it is usually managed long term with periodic review. For most people, treatment should continue indefinitely, especially as women age into the later decades when immune systems can be less robust and infections can be more dire, contributing to the risk of sepsis, falls and fractures.